Excellergy Inc

Excellergy Inc is a startup based in the United States. Its most recent tracked round is Series A. Brouky classifies it under Healthcare & Life Sciences.

Excellergy Inc develops first-in-class allergy therapeutics called Effector Cell Response Inhibitors (ECRIs) that rapidly disable the IgE axis by removing IgE from allergic effector cells, neutralizing free IgE, and downregulating receptor expression to control severe allergic diseases.